The next generation of PPAR drugs: Do we have the tools to find them?

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 8, 2007, Pages 1082-1093

  Shearer, Barry G ^a   Billin, Andrew N ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Drug discovery; PPAR; Safety; TZD

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ACETAMIDE DERIVATIVE; AMG 131; FIBRIC ACID DERIVATIVE; GW 0072; GW 677954; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LY 465608; MIFOBATE; PD 068235; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PLACEBO; PLX 204; RALOXIFENE; ROSIGLITAZONE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADIPOGENESIS; CARCINOGENESIS; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DYSLIPIDEMIA; EDEMA; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; WEIGHT GAIN;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA; SAFETY;

EID: 34547625616     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.05.005     Document Type: Review

References (69)

1. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
2. Escher P., et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142 10 (2001) 4195-4202
3. Spiegelman B.M., and Flier J.S. Adipogenesis and obesity: rounding out the big picture. Cell 87 3 (1996) 377-389
4. Luquet S., et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim. Biophys. Acta 1740 2 (2005) 313-317
5. Tanaka T., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100 26 (2003) 15924-15929
6. Lee C.H., et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 103 9 (2006) 3444-3449
7. Balint B.L., and Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr. Metab. Immune Disord. Drug Targets 6 1 (2006) 33-43
8. Barish G.D., Narkar V.A., and Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116 3 (2006) 590-597
9. Haluzik M.M., and Haluzik M. PPAR-alpha and insulin sensitivity. Physiol. Res. 55 2 (2006) 115-122
10. Berger J.P., Akiyama T.E., and Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 5 (2005) 244-251
11. Scheen A.J. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?. Drug Saf. 27 12 (2004) 841-856
12. Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance. Int. J. Clin. Pract. 60 10 (2006) 1272-1280
13. J. El-Hage, Clinical and Preclinical Safety Assessments for PPAR Agonists, in www.fda.gov, 2006.
14. Nesto R.W., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, October 7, 2003. Circulation 108 23 (2003) 2941-2948
15. Robinson J.G. Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE. Curr. Atheroscler. Rep. 9 1 (2007) 64-71
16. Boden G., and Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin. Investig. Drugs 15 3 (2006) 243-250
17. Patel C., Wyne K.L., and McGuire D.K. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. Diab. Vasc. Dis. Res. 2 2 (2005) 61-66
18. Guan Y., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11 8 (2005) 861-866
19. Zhang H., et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U. S. A. 102 26 (2005) 9406-9411
20. Nicholas S.B., et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 37 2 Part 2 (2001) 722-727
21. Chen L., et al. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther. 312 2 (2005) 718-725
22. Baer A.N., and Wortmann R.L. Myotoxicity associated with lipid-lowering drugs. Curr. Opin. Rheumatol. 19 1 (2007) 67-73
23. Jacobson T.A., and Zimmerman F.H. Fibrates in combination with statins in the management of dyslipidemia. J. Clin. Hypertens. (Greenwich) 8 1 (2006) 35-41 quiz 42-3
24. Johnson T.E., et al. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol. Appl. Pharmacol. 208 3 (2005) 210-221
25. Sprecher D.L., et al. Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler. Thromb. Vasc. Biol. 27 2 (2007) 359-365
26. Willson T.M., Lehmann J.M., and Kliewer S.A. Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann. N. Y. Acad. Sci. 804 (1996) 276-283
27. Wu X., et al. Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J. Biomol. Screen. 8 4 (2003) 381-392
28. Lehmann J.M., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 22 (1995) 12953-12956
29. Willson T.M., et al. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138 9 (1997) 3901-3911
30. Chawla A., et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 1 (2001) 48-52
31. Kim D.J., et al. PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13 1 (2006) 53-60
32. Chaput E., et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophys. Res. Commun. 271 2 (2000) 445-450
33. Guerre-Millo M., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275 22 (2000) 16638-16642
34. Buse J.B., et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27 8 (2005) 1181-1195
35. Calkin A.C., Thomas M.C., and Cooper M.E. MK-767. Kyorin/Banyu/Merck. Curr. Opin. Investig. Drugs 4 4 (2003) 444-448
36. Fagerberg B., et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 9 (2005) 1716-1725
37. Pickavance L.C., et al. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br. J. Pharmacol. 144 3 (2005) 308-316
38. Oliver Jr. W.R., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98 9 (2001) 5306-5311
39. Wang Y.X., et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113 2 (2003) 159-170
40. Liu K.G., et al. Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. 11 22 (2001) 2959-2962
41. Xu Y., et al. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile. J. Med. Chem. 49 19 (2006) 5649-5652
42. Ramachandran U., Kumar R., and Mittal A. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. Mini Rev. Med. Chem. 6 5 (2006) 563-573
43. Etgen G.J., et al. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51 4 (2002) 1083-1087
44. Miles P.D., et al. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105 3 (2000) 287-292
45. Olefsky J.M., and Saltiel A.R. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol. Metab. 11 9 (2000) 362-368
46. Shang Y., et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 6 (2000) 843-852
47. Rangwala S.M., and Lazar M.A. The dawn of the SPPARMs?. Sci. STKE 2002 121 (2002) PE9
48. Berger J.P., et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 17 4 (2003) 662-676
49. Oberfield J.L., et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 96 11 (1999) 6102-6106
50. Rocchi S., et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8 4 (2001) 737-747
51. Minoura H., et al. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur. J. Pharmacol. 494 2-3 (2004) 273-281
52. Fujimura T., et al. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J. Pharmacol. Exp. Ther. 318 2 (2006) 863-871
53. Fujimura T., et al. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J. Pharmacol. Sci. 99 4 (2005) 342-352
54. Minoura H., et al. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur. J. Pharmacol. 519 1-2 (2005) 182-190
55. Li Y., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27 11 (2004) 2597-2602
56. D. Altshuler, H.J., M. Klannemark, C.M. Lindgren, M.C. Vohl, J. Nemesh, S.S. Lane, C.R., S. Bolk, C. Brewer, T. Tuomi, D. Gaudet, T.J. Hudson, M. Daly, Groop, L.E. L, The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 26 (1) 76-80.
57. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto A.J., and W. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20 3 (1998) 284-287
58. Hara K., Okada T., Tobe K., Yasuda K., Mori Y., Kadowaki H., Hagura R., Akanuma Y., Kimura S., Ito C., and Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 271 1 (2000) 212-216
59. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., Ide T., Kubota N., Terauchi Y., Tobe K., Miki H., Tsuchida A., Akanuma Y., Nagai R., Kimura S., Kadowaki, and Tachibana K. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276 44 (2001) 41245-41254
60. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., and Spiegelman S.B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 275 3 (2000) 1873-1877
61. Camp H.S., Chaundhry A., and Leff T. A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 142 7 (2001) 3207-3213
62. Mukherjee R., Hoener P.A., Jow L., Bilakovics J., Klausing K., Mais D.E., Faulkner A., Croston G.E., and Paterniti Jr. J.R. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. 14 9 (2000) 1425-1433
63. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., Davis R.G., Hull-Ryde E.A., Lenhard J.M., Patel L., Plunket K.D., Shenk J.L., Stimmel J.B., Therapontos, C W.T., and Blanchard S.G. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 21 (2002) 6640-6650
64. Miyahara T., Schrum L., Rippe R., Xiong S., Yee Jr. H.F., Motomura K., Anania F.A., Willson T.M., and Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem. 275 46 (2000) 35715-35722
65. Nakano R., Kurosaki E., Yoshida S., Yokono M., Shimaya A., Maruyama T., and Shibasaki M. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem. Pharmacol. 72 1 (2006) 42-52
66. Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., and Wahli W. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. 16 11 (2002) 2628-2644
67. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., Parks D.J., Moore J.T., Kliewer S.A., Willson T.M., and JB S. Structural basis for antagonist-mediated recruitment of nuclear corepressors by PPARalpha. Nature 415 6873 (2002) 813-817
68. Etgen G.J., and Mantlo N. PPAR ligands for metabolic disorders. Curr. Top. Med. Chem. 3 14 (2003) 1649-1661
69. Pascual G., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 7059 (2005) 759-763